Historical Stock Price
ACRS historical stock prices picture
Aclaris Therapeutics (ACRS) has the following price history information. Looking back at ACRS historical stock prices for the last five trading days, on September 15, 2020, ACRS opened at $2.23, traded as high as $2.40 and as low as $2.23, and closed at $2.35. Trading volume was a total of 255.80K shares. On September 16, 2020, ACRS opened at $2.36, traded as high as $2.49 and as low as $2.32, and closed at $2.39. Trading volume was a total of 187.50K shares. On September 17, 2020, ACRS opened at $2.37, traded as high as $2.62 and as low as $2.32, and closed at $2.54. Trading volume was a total of 278.50K shares. On September 18, 2020, ACRS opened at $2.56, traded as high as $2.79 and as low as $2.39, and closed at $2.53. Trading volume was a total of 710.00K shares. On September 21, 2020, ACRS opened at $2.43, traded as high as $2.52 and as low as $2.40, and closed at $2.49. Trading volume was a total of 97.70K shares.

ACRS Historical Stock Prices By Date:

ACRS historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aclaris Therapeutics shares, starting with a $10,000 purchase of ACRS, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/06/2015
End date: 09/21/2020
Start price/share: $11.00
End price/share: $2.49
Dividends collected/share: $0.00
Total return: -77.36%
Average Annual Total Return: -25.86%
Starting investment: $10,000.00
Ending investment: $2,264.08
Years: 4.96
Date Open High Low Close Volume
09/15/2020 $2.23 $2.40 $2.23 $2.35 255.80K
09/16/2020 $2.36 $2.49 $2.32 $2.39 187.50K
09/17/2020 $2.37 $2.62 $2.32 $2.54 278.50K
09/18/2020 $2.56 $2.79 $2.39 $2.53 710.00K
09/21/2020 $2.43 $2.52 $2.40 $2.49 97.70K
Aclaris Therapeutics is a biopharmaceutical company focused on immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes: ATI-450 mitogen-activated protein kinase-activated protein kinase 2 Inhibitor Oral for the indication of Rheumatoid Arthritis plus Additional Immuno-inflammatory Indication; and ATI-1777 Janus kinase (JAK)1/JAK3 Inhibitor Soft Topical for the indication of Atopic Dermatitis. ESKATA, Co.'s only U.S. Food and Drug Administration (FDA)-approved product, is a formulation of high-concentration hydrogen peroxide topical solution which is approved by the FDA as an office-based prescription treatment for raised seborrheic keratosis, a non-malignant skin tumor.
Date Close
09/15/2020$2.35
09/16/2020$2.39
09/17/2020$2.54
09/18/2020$2.53
09/21/2020$2.49
ACRS is categorized under the Healthcare sector; below are some other companies in the same sector:

ACRX Historical Stock Prices
ACST Historical Stock Prices
ACT Historical Stock Prices
ACUR Historical Stock Prices
ADHD Historical Stock Prices
ADK Historical Stock Prices
ADMA Historical Stock Prices
ADMP Historical Stock Prices
ADMS Historical Stock Prices
ADPT Historical Stock Prices

Also explore: ACRS shares outstanding history


ACRS Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.